Symptom Control

Disease Group

Clinical Trials: ACCRU Clinical Trials Disease Groups
Breast Cancer Gastrointestinal Cancer Genitourinary Cancer Lung Cancer Lymphoma Myeloma Oncology / Other Symptom Control
Trial Spotlight

Symptom Control

Disease Group Profile

Charles Loprinzi has been leading the ACCRU Cancer Control Program since ACCRU (and its precursor organization, MCCRC) started in 2005. Work in this area has included 15 trials related to cancer screening, cancer prevention, and symptom control. This program welcomes individuals to reach out if there are questions and/or ideas about conducting such trials.

Disease Group Leaders

Charles Loprinzi, M.D.

Symptom Control Program Lead

Charles Loprinzi, M.D. coordinates the ACCRU cancer control program and is the only leadership person that has been with ACCRU since it was initiated. His primary research focus deals with symptom control trials which he defines as trials aimed at trying to prevent and/or treat and/or better understand symptoms caused by cancer and/or cancer treatment.

Meet Charles »

Disease Group Clinical Trials

ACCRU-SC-2102
Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy »
No posts found.
39039039STM4001

Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants »

ACCRU-SC-1601

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban For Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy »

ACCRU-SC-1603

A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes

Oxybutynin Chloride in Managing Hot Flashes »

RC11C3

Pilot Placebo-Controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome

Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel »

RU221408I

Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Neuropathy (CIPN) and Paclitaxel-induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Study

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel »

RU221501I

A Phase III, Randomized, Open Label Study Evaluating the Safety and Efficacy of Apixaban in Subjects With Cancer Related Venous Thromboembolism

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism »

RU221511I

Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial

Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome »

 More from ACCRU Clinical Trials »